Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Immuno-Oncology | Specialty
home
Content Type
CDK4/6 Inhibition in Hormone Receptor-Positive mBC
January 22nd 2020
Strategies for Hormone Receptor-Positive Metastatic BC
January 22nd 2020
HER2+ Breast Cancer: Future Treatment Landscape
January 11th 2020
Practical Advice on Treating HER2+ Metastatic Breast Cancer
January 11th 2020
Targeting HER2 Outside of Breast Cancer
January 11th 2020
Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC
January 11th 2020
Emerging Agents for HER2+ mBC: Targeted Therapeutics
January 11th 2020
Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials
January 11th 2020
Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC
January 11th 2020
HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study
January 11th 2020
HER2+ mBC: Study Design and Results of DESTINY-Breast01
January 11th 2020
HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates
January 11th 2020
Unmet Needs in the Management of HER2+ mBC
January 11th 2020
Treatment Strategies for Relapsed/Refractory HER2+ mBC
January 11th 2020
HER2+ BC: Selection and Management of Neoadjuvant Therapy
January 11th 2020
Overview of Neoadjuvant Therapy in HER2+ Breast Cancer
January 11th 2020
Early-Stage HER2+ Breast Cancer: The ATEMPT Trial
January 11th 2020
Impact of the KATHERINE Trial on Early-Stage HER2+ BC
January 11th 2020
Adjuvant Strategies in Early-Stage HER2+ Breast Cancer
January 11th 2020
Evolving Landscape of HER2-Targeted Therapy in Breast Cancer
January 11th 2020
NEXT PAGE
<
1
...
40
41
42
43
44
45
46
47
48
...
194
>
PREVIOUS PAGE